Boston Scientific Targets Growing Aortic Stenosis Market With $1.5 Billion Deal

Boston Scientific Corporation (NYSE:BSX) said it invested $1.5 billion in privately held MiRus, securing an approximately 34% equity stake and an exclusive option to acquire the company's investigational transcatheter aortic valve replacement (TAVR) business.